Protein-bound paclitaxel explained

Verifiedfields:changed
Verifiedrevid:443693471
Type:combo
Component1:Paclitaxel
Class1:Mitotic inhibitor
Component2:Albumin
Class2:Delivery vehicle
Tradename:Abraxane, others
Dailymedid:Paclitaxel
Pregnancy Au:D
Routes Of Administration:Intravenous
Atc Prefix:L01
Atc Suffix:CD01
Legal Au:S4
Legal Ca:Rx-only
Legal Ca Comment:[1]
Legal Uk:POM
Legal Us:Rx-only
Legal Eu:Rx-only
Legal Status:Rx-only
Chemspiderid:none
Cas Number:33069-62-4
Unii:P88XT4IS4D
Drugbank:DB01229
Kegg:D00491

Protein-bound paclitaxel, also known as nanoparticle albumin–bound paclitaxel or nab-paclitaxel, is an injectable formulation of paclitaxel used to treat breast cancer, lung cancer and pancreatic cancer, among others. Paclitaxel kills cancer cells by preventing the normal breakdown of microtubules during cell division.[2] [3] In this formulation, paclitaxel is bonded to albumin as a delivery vehicle.[4] It is manufactured and sold in the United States by Celgene under the trade name Abraxane where it is designated as an orphan drug as first-line treatment, in combination with gemcitabine, for the orphan disease "metastatic adenocarcinoma of the pancreas".[5]

This treatment was approved in the United States in 2005,[6] and the European Union in 2008, for breast cancer cases where cancer did not respond to other chemotherapy or has relapsed.[7] [8] In 2012, the FDA widened the approved uses to include treatment for NSCLC.[9] [10] In 2013, the FDA approved protein-bound paclitaxel for use in treating advanced pancreatic cancer as a less toxic (although less effective) alternative to FOLFIRINOX.[11]

Society and culture

Abraxane is registered on the Australian Register of Therapeutic Goods for the treatment of metastatic carcinoma of the breast after failure of anthracycline therapy.[12] Abraxane is also included on the Schedule of the Australian Pharmaceutical Benefits Scheme although[13] the manufacturer was unable to convince the independent Pharmaceutical Benefits Advisory Committee that the drug warranted a higher price than existing comparator drugs.[14] Protein-bound paclitaxel was developed by VivoRx which became Abraxis BioScience as the first in its class of drugs to use the nanoparticle albumin bound (nab) technology platform.[15]

In 2010, Abraxis was acquired by Celgene, which now markets Abraxane.[16] Total revenue from the sales of Abraxane for 2009 were $314.5 million.[17] In 2013, Abraxane was FDA approved for the treatment of pancreatic cancer.[18] In 2014, Abraxane's sales were $848 million, 31 percent year-over-year increase.[19] In 2019 Bristol Meyers Squibb acquired Celgene for $74 billion dollars, and thus acquired Abraxis Bioscience and the rights to manufacture and market Abraxane.[20]

The UK's National Institute for Health and Care Excellence (NICE) announced in 2015, that it would not support the routine use of protein-bound paclitaxel in advanced pancreatic cancer on the NHS.[21] However, this decision was changed in September 2017.[22] It has continued to be reimbursed in England since then, despite questionable real world effectiveness.[23]

Further reading

Notes and References

  1. Web site: Product monograph brand safety updates . . 7 July 2016 . 3 April 2024.
  2. Web site: Definition of "protein-bound paclitaxel" . National Cancer Institute Dictionary of Cancer Terms . 2011-02-02. mdy-all .
  3. Web site: Nab-paclitaxel (Abraxane) . 2025-04-13 . www.cancerresearchuk.org . en.
  4. Web site: Paclitaxel Albumin-stabilized Nanoparticle Formulation . National Cancer Institute Drug Information . 2006 .
  5. Web site: Abraxane. Orpha Net . September 6, 2013 . July 20, 2015 .
  6. Knapp A . August 27, 2020. The Inside Story Of Biotech's Barnum And His Covid Cures. 2020-08-27. Forbes. en.
  7. Web site: FDA Approval for Nanoparticle Paclitaxel . National Cancer Institute Drug Information . 2006 . 18 February 2008 . 24 July 2008 . https://web.archive.org/web/20080724085354/http://www.cancer.gov/cancertopics/druginfo/fda-nanoparticle-paclitaxel . dead .
  8. Web site: Abraxane EPAR . European Medicines Agency (EMA) . 9 March 2020 . 9 March 2020.
  9. News: FDA approves Celgene's Abraxane for lung cancer . mdy-all . Reuters . 2012-10-12 .
  10. Web site: Paclitaxel (Abraxane). https://web.archive.org/web/20121014154607/http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm323668.htm. dead. 14 October 2012. U.S. Food and Drug Administration. October 11, 2012. 10 December 2012.
  11. News: Pollack A . F.D.A. Approves a Drug for Late-Stage Pancreatic Cancer . . September 7, 2013 . September 6, 2013.
  12. Web site: Resolution 9190. Therapeutic Goods Administration (Tga). June 6, 2008.
  13. Vines T, Faunce T . Assessing the safety and cost-effectiveness of early nanodrugs . Journal of Law and Medicine . 16 . 5 . 822–845 . May 2009 . 19554862 .
  14. Web site: PBAC, Public Summary Document. November 2008. health.gov.au.
  15. Web site: Celgene: A Global Biopharmaceutical Company Committed to Improving the Lives of Patients Worldwide with Innovative and Life-Changing Treatments. www.abraxisbio.com.
  16. Celgene Completes Acquisition of Abraxis. Celgene.
  17. Web site: Abraxis Reports Phase III Success with Abraxane in First-Line NSCLC . 2010. www.genengnews.com/ .
  18. FDA. FDA approves Abraxane for late-stage pancreatic cancer. https://web.archive.org/web/20130909082039/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm367442.htm. dead. 9 September 2013.
  19. Celgene. Celgene Corporation Announces 2015 and Long-Term Financial Outlook and Preliminary 2014 Results (NASDAQ:CELG).
  20. Web site: Kansteiner . Fraiser . Bristol Myers' subsidiary behind cancer blockbuster Abraxane slapped with FDA warning letter . Fierce Pharma . 2022-11-09 . 2025-03-12.
  21. Web site: NHS England stop access to Abraxane - Pancreatic Cancer UK. September 2015. www.pancreaticcancer.org.uk/. 24 December 2015. 25 December 2015. https://web.archive.org/web/20151225115559/http://www.pancreaticcancer.org.uk/latest-news/2015/september/last-hope-dashed-for-access-to-life-extending-pancreatic-cancer-drug-on-the-nhs-in-england/#sthash.PpHk2Lur.dpuf. dead.
  22. Web site: 2017-09-06 . Overview Paclitaxel as albumin-bound nanoparticles with gemcitabine for untreated metastatic pancreatic cancer Guidance NICE . 2024-12-26 . www.nice.org.uk.
  23. Wadd N, Peedell C, Polwart C . Real-World Assessment of Cancer Drugs Using Local Data Uploaded to the Systemic Anti-Cancer Therapy Dataset in England . Clinical Oncology . 34 . 8 . 497–507 . August 2022 . 35584974 . 10.1016/j.clon.2022.04.012 .